Research Analysts Issue Forecasts for MLYS Q3 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Stock analysts at HC Wainwright raised their Q3 2025 earnings per share estimates for Mineralys Therapeutics in a report issued on Wednesday, August 13th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.74) per share for the quarter, up from their prior estimate of ($0.92). HC Wainwright has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.01) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.20) EPS and FY2029 earnings at $1.72 EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.12.

A number of other research firms have also recently issued reports on MLYS. Jefferies Financial Group assumed coverage on Mineralys Therapeutics in a research note on Tuesday, June 10th. They issued a “hold” rating and a $15.00 target price for the company. Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Finally, Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Hold” and an average target price of $32.25.

Mineralys Therapeutics Trading Up 2.8%

NASDAQ:MLYS opened at $14.52 on Friday. Mineralys Therapeutics has a 1 year low of $8.24 and a 1 year high of $18.38. The stock has a market cap of $962.53 million, a price-to-earnings ratio of -4.08 and a beta of -0.29. The stock has a 50-day moving average price of $14.05 and a two-hundred day moving average price of $13.53.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MLYS. SBI Securities Co. Ltd. boosted its position in Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company’s stock valued at $25,000 after purchasing an additional 1,190 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Mineralys Therapeutics during the fourth quarter valued at approximately $48,000. Ameritas Investment Partners Inc. boosted its position in Mineralys Therapeutics by 42.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Mineralys Therapeutics during the second quarter valued at approximately $91,000. 84.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Mineralys Therapeutics

In other news, insider David Malcom Rodman sold 11,366 shares of the company’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.59, for a total transaction of $165,829.94. Following the completion of the transaction, the insider directly owned 97,907 shares of the company’s stock, valued at $1,428,463.13. This represents a 10.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jon Congleton sold 15,884 shares of the stock in a transaction that occurred on Friday, July 11th. The shares were sold at an average price of $14.51, for a total value of $230,476.84. Following the transaction, the chief executive officer directly owned 846,405 shares of the company’s stock, valued at $12,281,336.55. This trade represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,051 shares of company stock valued at $1,776,262 over the last three months. Company insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.